Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

iPS-ChOp-AF

Financiado

Combining induced pluripotent stem cells tissue engineering optogenetic and ch...

Combining induced pluripotent stem cells tissue engineering optogenetic and chemogenetic concepts for the study and treatment of atrial fibrillation "Cardiac arrhythmias are responsible for significant morbidity and mortality. However, the study and treatment of these rhythm disorders have been hampered by the lack of relevant human cardiac tissue models, specifically those re... ver más

31/08/2023

TECHNION ISRAEL I...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

TECHNION ISRAEL INSTITUTE OF TECHNOLOGY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-08-31

ERC-2017-COG: ERC Consolidator Grant

I+D

Cerrada hace 7 años

0% 100% 100%

2 Participantes

TECHNION ISRAEL INSTITUTE O...

1.99M€ | Lider

R BELDA LLORENS

547.90K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

STOP-HF STEM CELL MODELS TO UNRAVEL THE SUSCEPTIBILITY AND RESILIENC... 1M€ Cerrado

DISSECT-HF Dynamic engIneered heart tiSsue to Study intEr-individual su... 2M€ Cerrado

3-D Cardioid Decoding enhancer usage and gene expression of human heart d... 190K€ Cerrado

Edit-hCOs Precise Genome Editing to Correct Cardiomyopathies in Human... 189K€ Cerrado

3DCardiacHTS Bringing 3D cardiac tissues to high throughput for drug disc... 1M€ Cerrado

G-CYBERHEART Computationally and experimentallY BioEngineeRing the next g... 1M€ Cerrado

Duración del proyecto: 66 meses Fecha Inicio: 2018-02-18
Fecha Fin: 2023-08-31

Líder del proyecto

TECHNION ISRAEL INSTITUTE OF TECHNOLOGY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto "Cardiac arrhythmias are responsible for significant morbidity and mortality. However, the study and treatment of these rhythm disorders have been hampered by the lack of relevant human cardiac tissue models, specifically those reflecting patient/disease-specific abnormalities, by paucity of methods for long-term electrophysiological analysis of the tissue, and by the inability to perform targeted, high-resolution, reversible, and functional perturbations of the system. To address these challenges, we propose to combine human induced pluripotent stem cells (hiPSC) and genome-editing (CRISPR) technologies, developmental biology-inspired differentiating systems that yield chamber-specific heart cells, novel tissue engineering strategies, and emerging concepts from the fields of optogenetics and chemogenetics. The resulting experimental models should represent a paradigm shift in the way we study and treat cardiac arrhythmias. To demonstrate the unique potential of this approach, we plan to focus on atrial fibrillation (AF), the most common arrhythmia. Our specific aims are to: 1. Develop patient/disease-specific hiPSC models of genetic AF and to establish hiPSC differentiation protocols to yield purified atrial cells 2. Utilize the hiPSC-atrial cells and advanced tissue-engineering strategies (hydrogels, 3D printing, decellularization) to establish 2D cell-sheet and 3D tissue models of acquired and inherited AF, in which functional re-entry (""rotors"") can be studied 3. Utilize tools from optogenetics (light-sensitive ion channels and pumps) or chemogenetics (ligand-specific engineered receptors) for targeted manipulation of the system, to gain insights into AF pathogenesis and to develop novel therapies 4. Evaluate the developed optogenetic and chemogenetic treatments in animal models of AF The results of this project should provide novel mechanistic insights into AF (and other arrhythmias) and open the road for the development of novel therapeutic paradigms."

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores